Literature DB >> 26393116

Emerging Role of Myeloperoxidase in the Prognosis of Nephrotic Syndrome Patients Before and After Steroid Therapy.

Sreelatha Souparnika1, Benedicta D'Souza2, Vivian D'Souza2, Sushanth Kumar3, Poornima Manjrekar4, Manohar Bairy3, Rajeevalochana Parthasarathy5, Srinivas Kosuru5.   

Abstract

BACKGROUND: Myeloperoxidase (MPO) is a myelocyte derived iron containing enzyme particularly involved in host defense by destroying foreign micro organisms invading the body. Numerous evidences suggest that MPO is involved in the pathogenesis of many inflammatory diseases, especially atherosclerosis. AIM: Present study deals with the role of MPO in the renal function and progression of disease in Nephrotic syndrome patients. STUDY DESIGN AND SETTINGS: Case- Control Study carried out in Kasturba Medical College Hospital, Mangalore, India.
MATERIALS AND METHODS: Forty newly diagnosed Nephrotic syndrome cases, 40 age and sex matched healthy controls and 15 subjects in Nephrotic syndrome remission, were included in the study. Myeloperoxidase enzyme was assayed by 4 amino antipyrine methods in all the subjects. Other renal parameters like urea, creatinine, Blood Urea Nitrogen (BUN), BUN- Creatinine ratio (BUN/Cr) total protein, albumin, globulin, albumin - globulin ratio (A/G ratio) and estimated Glomerular Filtration Rate (eGFR) were also analysed. 24 hour urine protein-creatinine ratio was estimated in Nephrotic syndrome cases and remission group by turbidimetric assay. STATISTICAL ANALYSIS: Students paired t-test and Wilcoxon Signed Rank test were used for the comparison of the data. Pearson and Spearman analyses were used for correlation of the parameters.
RESULTS: MPO levels were found to be high in Nephrotic syndrome cases when compared to healthy controls. Urea, creatinine, BUN, BUN/Cr ratio and eGFR were high in Nephrotic syndrome cases while total protein, albumin, globulin and A/G ratio showed decreased levels. MPO had a positive correlation with creatinine and urine protein-creatinine ratio in Nephrotic syndrome. During remission, MPO levels decreased significantly while total protein and albumin levels increased.
CONCLUSION: Myeloperoxidase enzyme is found to be elevated and it strongly correlated with the severity of disease in Nephrotic syndrome. Further studies can be done to use MPO as a therapeutic target in Nephrotic syndrome to ameliorate the symptoms.

Entities:  

Keywords:  Nephrotic Syndrome; Protein-creatinine ratio; Remission

Year:  2015        PMID: 26393116      PMCID: PMC4572946          DOI: 10.7860/JCDR/2015/12532.6222

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  21 in total

Review 1.  Role of oxidants and proteases in glomerular injury.

Authors:  R J Johnson; D Lovett; R I Lehrer; W G Couser; S J Klebanoff
Journal:  Kidney Int       Date:  1994-02       Impact factor: 10.612

2.  New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system.

Authors:  R J Johnson; W G Couser; E Y Chi; S Adler; S J Klebanoff
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

3.  Analysis of the peptide subunits of human neutrophil myeloperoxidase.

Authors:  W M Nauseef; H L Malech
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

4.  Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome.

Authors:  Huseyin Begenik; Yasemin Usul Soyoral; Reha Erkoc; Habib Emre; Abdullah Taskın; Mehmet Tasdemir; Mehmet Aslan
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

5.  Steroids reduce local inflammatory mediator secretion and mucosal permeability in collagenous colitis patients.

Authors:  Yesuf Taha; Yngve Raab; Marie Carlson; Anders Larsson; Mikael Lördal; Lars Lööf; Magnus Thörn
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

Review 6.  Myeloperoxidase: a front-line defender against phagocytosed microorganisms.

Authors:  Seymour J Klebanoff; Anthony J Kettle; Henry Rosen; Christine C Winterbourn; William M Nauseef
Journal:  J Leukoc Biol       Date:  2012-10-11       Impact factor: 4.962

Review 7.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 8.  Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease.

Authors:  Sanjeev Sirpal
Journal:  Clin Sci (Lond)       Date:  2009-05       Impact factor: 6.124

Review 9.  Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein.

Authors:  Baohai Shao; Michael N Oda; John F Oram; Jay W Heinecke
Journal:  Chem Res Toxicol       Date:  2010-03-15       Impact factor: 3.739

Review 10.  Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?

Authors:  Roger K Schindhelm; Leonard P van der Zwan; Tom Teerlink; Peter G Scheffer
Journal:  Clin Chem       Date:  2009-06-25       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.